Fiche publication
Date publication
décembre 2024
Journal
Neuro-oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ENTZ-WERLE Natacha
,
Pr GAUCHOTTE Guillaume
,
Dr LHERMITTE Benoît
Tous les auteurs :
Filser M, Torrejon J, Merchadou K, Dufour C, Girard E, Bourneix C, Lemaître E, Gharsalli T, Brillet R, Wong J, Gentien D, Rapinat A, Servant N, Vasiljevic A, Bertozzi AI, Raimbault S, Tauziede Espariat A, Lhermitte B, Faure-Conter C, Icher C, Berger C, Maurage CA, Bodet D, Meyronet D, Uro-Coste E, De Carli E, Forest F, Palenzuela G, Chotard G, Gauchotte G, Sudour H, Mansuy L, Deparis M, Tallegas M, Faisant M, Entz-Werle N, Varlet P, Leblond P, Michalak-Provost S, Proust Houdemont S, Rigau V, Doz F, Delattre O, Bourdeaut F, Ayrault O, Masliah-Planchon J
Lien Pubmed
Résumé
Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into four molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis. It is critical to establish effective subtyping methods for accurate diagnosis and patient's management that strikes a delicate balance between improving outcomes and minimizing the risk of comorbidities.
Mots clés
Brain Tumors, Medulloblastoma Subgrouping, Methylation, Nanopore Sequencing
Référence
Neuro Oncol. 2024 12 28;:
